September 28, 2023: ASRI names Andrew N. Barynski, Ph.D. as Chief Operations Officer. Congratulations Dr. Bartynski!
June 13, 2023: In a pilot study designed to detect deuterated MDMA (MDMA-d3) in a test subject, ASRI scientists report the first observation of MDMA-d3 in human urine using enzyme-linked immunoassay (ELISA) and LC-MS/MS mass spectral analysis.
November 23, 2022: The first FDA-approved clinical trial to explore a low dose psilocybin pulse regimen for the suppression of cluster headache is conducted at Yale University. The psilocybin was synthesized and provided by ASRI scientists, who co-authored the manuscript.
October 14, 2022: ASRI Founder and President, Dr. Nicholas V. Cozzi, presents ASRI research at the Horizons New York 2022: Perspectives on Psychedelics Conference, New York City, October 12-16, 2022.
July 6, 2022: The Alexander Shulgin Research Institute and CaaMTech announce collaboration to study novel compounds from the Shulgin Vault. Shulgin compounds will be studied by X-ray diffraction crystallography at Dr. David Manke’s lab at UMass-Dartmouth.
June 3, 2022: The first FDA-approved clinical study of the safety, tolerability, and efficacy of N,N-dimethyltryptamine (DMT) in Major Depressive Disorder is co-authored by ASRI scientists, who synthesized the DMT hemifumarate employed in the study.